Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Health profiles of 996 melanoma survivors: the M. D. Anderson experience

Authors: Charles Stava, Martha Beck, L Todd Weiss, Adriana Lopez, Rena Vassilopoulou-Sellin

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

The incidence and survival of melanoma are increasing, but little is known about its long-term health effects in adult survivors.

Methods

A health survey was available from 996 melanoma survivors (577 treated with surgery alone, and 391 with combined treatments). Their medical/physiologic and psychosocial responses were analyzed and compared with those of the survivors from other cancers.

Results

The melanoma survivors were 44.8 ± 12.8 years of age at diagnosis (significantly younger than the survivors of other cancers) and 63.7 ± 12.8 years at survey. Melanoma survivors were less likely to report that cancer had affected their health than survivors of other cancers (15.8% vs. 34.9%). The 577 individuals treated with surgery alone reported arthritis/osteoporosis, cataracts, and heart problems most frequently (less often than survivors of other cancers). The 391 individuals who had undergone combined treatments reported circulation problems and kidney problems generally as often as survivors of other cancers. Health problems were not associated with number of decades since diagnosis but with age at diagnosis, treatment modality, and family relationships.

Conclusion

We present information from a large cohort of long-term survivors of melanoma. As a group, they were less likely to report that cancer had affected their overall health than survivors of other cancers; a number of disease related and psychosocial factors appear to influence their health profiles.
Appendix
Available only for authorised users
Literature
2.
go back to reference Lotze MT, Dallal RM: Cutaneous melanoma. Principles and practices of oncology. Edited by: DeVita VT, Rosenberg SA, Hellman S. 2001, Philadelphia: Lippincott, 6 Lotze MT, Dallal RM: Cutaneous melanoma. Principles and practices of oncology. Edited by: DeVita VT, Rosenberg SA, Hellman S. 2001, Philadelphia: Lippincott, 6
4.
go back to reference Meric JB, Rixe O, Khayat D: Metastatic malignant melanoma. Drugs Today (Barc). 2003, 39 (suppl C): 17-38. Meric JB, Rixe O, Khayat D: Metastatic malignant melanoma. Drugs Today (Barc). 2003, 39 (suppl C): 17-38.
6.
go back to reference Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK: Cutaneous melanoma. Principles and practices of oncology. Edited by: DeVita VT, Rosenberg SA, Hellman S. 1997, Philadelphia: Lippincott, 5 Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK: Cutaneous melanoma. Principles and practices of oncology. Edited by: DeVita VT, Rosenberg SA, Hellman S. 1997, Philadelphia: Lippincott, 5
7.
go back to reference Berwick M, Weinstock MA: Epidemiology current trends in cutaneous melanoma. Edited by: St Louis. 2003, Quality Medical Publishing, 4 Berwick M, Weinstock MA: Epidemiology current trends in cutaneous melanoma. Edited by: St Louis. 2003, Quality Medical Publishing, 4
8.
go back to reference Christianson DF, Anderson CM: Close monitoring and lifetime follow up is optimal for patients with a history of melanoma. Semin Oncol. 2003, 3: 369-374. 10.1016/S0093-7754(03)00097-6.CrossRef Christianson DF, Anderson CM: Close monitoring and lifetime follow up is optimal for patients with a history of melanoma. Semin Oncol. 2003, 3: 369-374. 10.1016/S0093-7754(03)00097-6.CrossRef
9.
go back to reference Hewitt M, Greenfield S, Stovall E: From Cancer Patient to Cancer Survivor: Lost in Transition. 2006, Washington DC: National Academies Press Hewitt M, Greenfield S, Stovall E: From Cancer Patient to Cancer Survivor: Lost in Transition. 2006, Washington DC: National Academies Press
10.
go back to reference Schultz PN, Stava C, Beck M, Vassilopoulou-Sellin R: Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003, 104: 488-495. 10.1002/ijc.10981.CrossRefPubMed Schultz PN, Stava C, Beck M, Vassilopoulou-Sellin R: Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003, 104: 488-495. 10.1002/ijc.10981.CrossRefPubMed
11.
go back to reference NHIS data from Vital and Health Statistics Series 10, Number 222. National Health Interview Survey, US Department of Health and Human Services, Hyattsville MD. 2002 NHIS data from Vital and Health Statistics Series 10, Number 222. National Health Interview Survey, US Department of Health and Human Services, Hyattsville MD. 2002
12.
go back to reference Meadows AT, Hobbie WL: The medical consequences of care. Cancer. 1986, 15 (suppl 2): 524-528.CrossRef Meadows AT, Hobbie WL: The medical consequences of care. Cancer. 1986, 15 (suppl 2): 524-528.CrossRef
13.
go back to reference Reid , Zietz H, Jaffe N: Late effects of cancer treatment in children. Pediatr Dent. 1995, 17: 273-284. Reid , Zietz H, Jaffe N: Late effects of cancer treatment in children. Pediatr Dent. 1995, 17: 273-284.
14.
go back to reference Marina N: Long-term survivors of childhood cancer. The medical consequences of cure. Pediatr Clin North Am. 1997, 44: 1021-1042. 10.1016/S0031-3955(05)70543-5.CrossRefPubMed Marina N: Long-term survivors of childhood cancer. The medical consequences of cure. Pediatr Clin North Am. 1997, 44: 1021-1042. 10.1016/S0031-3955(05)70543-5.CrossRefPubMed
15.
go back to reference Stevens MC, Mahler H, Parks S: The health status of adult survivors of cancer in childhood. Eur J Cancer. 1998, 34: 694-698. 10.1016/S0959-8049(98)00012-4.CrossRefPubMed Stevens MC, Mahler H, Parks S: The health status of adult survivors of cancer in childhood. Eur J Cancer. 1998, 34: 694-698. 10.1016/S0959-8049(98)00012-4.CrossRefPubMed
16.
go back to reference Gotay CC, Muraoka MY: Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst. 1998, 90: 656-667. 10.1093/jnci/90.9.656.CrossRefPubMed Gotay CC, Muraoka MY: Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst. 1998, 90: 656-667. 10.1093/jnci/90.9.656.CrossRefPubMed
17.
go back to reference Welch-McCaffrey D, Hoffman B, Leigh SA, Loescher LJ, Meyskens FL: Surviving adult cancers. Part 2: psychosocial implications. Ann Intern Med. 1998, 111: 517-524.CrossRef Welch-McCaffrey D, Hoffman B, Leigh SA, Loescher LJ, Meyskens FL: Surviving adult cancers. Part 2: psychosocial implications. Ann Intern Med. 1998, 111: 517-524.CrossRef
18.
go back to reference Loescher LJ, Welch-McCaffrey D, Leigh SA, Hoffman B, Meyskens FL: Surviving adult cancers. Part 1 physiologic effects. Ann Intern Med. 1998, 111: 411-432.CrossRef Loescher LJ, Welch-McCaffrey D, Leigh SA, Hoffman B, Meyskens FL: Surviving adult cancers. Part 1 physiologic effects. Ann Intern Med. 1998, 111: 411-432.CrossRef
19.
go back to reference Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR: Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002, 94: 39-49.CrossRefPubMed Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR: Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002, 94: 39-49.CrossRefPubMed
20.
go back to reference Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavere P, Barats JC, Monnier A, Veyret C, Patchary J, Van Praagh I, Chapelle-Marcillac I: Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol. 2004, 22: 3070-3079. 10.1200/JCO.2004.03.098.CrossRefPubMed Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavere P, Barats JC, Monnier A, Veyret C, Patchary J, Van Praagh I, Chapelle-Marcillac I: Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol. 2004, 22: 3070-3079. 10.1200/JCO.2004.03.098.CrossRefPubMed
21.
go back to reference Rutqvist LE, Liedberg A, Hammer N, Dalberg K: Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998, 40: 359-363. 10.1016/S0360-3016(97)00765-7.CrossRefPubMed Rutqvist LE, Liedberg A, Hammer N, Dalberg K: Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998, 40: 359-363. 10.1016/S0360-3016(97)00765-7.CrossRefPubMed
22.
go back to reference Bloom JR, Fobair P, Gritz E, Wellisch D, Speigel D, Varghese A, Hoppe R: Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer. J Clin Oncol. 1993, 11: 979-988.PubMed Bloom JR, Fobair P, Gritz E, Wellisch D, Speigel D, Varghese A, Hoppe R: Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer. J Clin Oncol. 1993, 11: 979-988.PubMed
23.
go back to reference Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X, Thompson EI, Wilimas JA, Kun LE, Crist WM: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol. 1998, 16: 3592-3600.PubMed Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X, Thompson EI, Wilimas JA, Kun LE, Crist WM: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol. 1998, 16: 3592-3600.PubMed
24.
go back to reference Vaughn DJ, Gignac GA, Meadows AT: Long-term medical care of testicular cancer survivors. Ann Intern Med. 2002, 136: 463-470.CrossRefPubMed Vaughn DJ, Gignac GA, Meadows AT: Long-term medical care of testicular cancer survivors. Ann Intern Med. 2002, 136: 463-470.CrossRefPubMed
25.
go back to reference Joly F, Heron JF, Kalusinski L, Bottet P, Brune D, Allouache N, Mace-Lese'h J, Couette JE, Peny J, Henry-Amar M: Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol. 2002, 20: 73-80. 10.1200/JCO.20.1.73.CrossRefPubMed Joly F, Heron JF, Kalusinski L, Bottet P, Brune D, Allouache N, Mace-Lese'h J, Couette JE, Peny J, Henry-Amar M: Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol. 2002, 20: 73-80. 10.1200/JCO.20.1.73.CrossRefPubMed
26.
go back to reference Fossa SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol. 2003, 21: 1249-1254. 10.1200/JCO.2003.08.163.CrossRefPubMed Fossa SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol. 2003, 21: 1249-1254. 10.1200/JCO.2003.08.163.CrossRefPubMed
27.
go back to reference Theuws JCM, Muller SH, Seppenwoolde Y, Kwa SL, Boersma LJ, Hart GA, Baas P, Lebesque JV: Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: a follow-up study. J Clin Oncol. 1999, 17: 3091-3100.PubMed Theuws JCM, Muller SH, Seppenwoolde Y, Kwa SL, Boersma LJ, Hart GA, Baas P, Lebesque JV: Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: a follow-up study. J Clin Oncol. 1999, 17: 3091-3100.PubMed
28.
go back to reference Dorresteijn LDA, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB, Van Leeuwen FE, Bartelink H: Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002, 20: 282-288. 10.1200/JCO.20.1.282.CrossRefPubMed Dorresteijn LDA, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB, Van Leeuwen FE, Bartelink H: Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002, 20: 282-288. 10.1200/JCO.20.1.282.CrossRefPubMed
29.
go back to reference Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998, 16: 3493-3501.PubMed Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998, 16: 3493-3501.PubMed
30.
go back to reference Trivedi A, Hannan MA: Radiation and cardiovascular diseases. J Environ Pathol Toxicol Oncol. 2004, 23: 99-106. 10.1615/JEnvPathToxOncol.v23.i2.20.CrossRefPubMed Trivedi A, Hannan MA: Radiation and cardiovascular diseases. J Environ Pathol Toxicol Oncol. 2004, 23: 99-106. 10.1615/JEnvPathToxOncol.v23.i2.20.CrossRefPubMed
31.
go back to reference Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M: The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Quality of Life Research. 1993, 2: 193-203. 10.1007/BF00435223.CrossRefPubMed Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M: The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Quality of Life Research. 1993, 2: 193-203. 10.1007/BF00435223.CrossRefPubMed
32.
go back to reference Gruss C, Geissler A, Schalke B, Landthaler M, Stolz W: Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation. Melanoma Res. 2002, 12: 403-404. 10.1097/00008390-200208000-00015.CrossRefPubMed Gruss C, Geissler A, Schalke B, Landthaler M, Stolz W: Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation. Melanoma Res. 2002, 12: 403-404. 10.1097/00008390-200208000-00015.CrossRefPubMed
33.
go back to reference Reimer J, Esser J, Fleiss A, Hessel A, Anastassiou G, Krausz M, Bornfeld N, Franke GH: Quality of life in patients with malignant choroidal melanoma after radiotherapy. Graefes Arch Clin Exp Opthalmol. 2003, 241: 371-377.CrossRef Reimer J, Esser J, Fleiss A, Hessel A, Anastassiou G, Krausz M, Bornfeld N, Franke GH: Quality of life in patients with malignant choroidal melanoma after radiotherapy. Graefes Arch Clin Exp Opthalmol. 2003, 241: 371-377.CrossRef
34.
go back to reference Brown JE, King MT, Butow PN, Dunn SM, Coates AS: Patterns over time in quality of life, coping, and psychological adjustment in late stage melanoma patients: an application of multilevel models. Qual Life Res. 2000, 9: 75-85. 10.1023/A:1008995814965.CrossRefPubMed Brown JE, King MT, Butow PN, Dunn SM, Coates AS: Patterns over time in quality of life, coping, and psychological adjustment in late stage melanoma patients: an application of multilevel models. Qual Life Res. 2000, 9: 75-85. 10.1023/A:1008995814965.CrossRefPubMed
Metadata
Title
Health profiles of 996 melanoma survivors: the M. D. Anderson experience
Authors
Charles Stava
Martha Beck
L Todd Weiss
Adriana Lopez
Rena Vassilopoulou-Sellin
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-95

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine